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1. Introduction  
Activation of oncogenic proteins is an important mechanism in carcinogenesis. The BRAF 
gene, located on chromosome 7q34, encodes a serine-threonine kinase that acts downstream 
of RAS in the RAS/RAF/MEK/ERK signaling pathway involved in regulating cell 
proliferation and survival. On activation of RAS, the BRAF kinase is activated and 
sequentially phosphorylates and activates MEK and ERK. A mutation in BRAF leads to 
constitutive hyperactivation of this pathway through evasion of the inhibitory feedback loop 
resulting in increased ERK signaling output which drives proliferative and anti-apoptotic 
signaling (Pratilas et al. 2009). Mutations in BRAF have been reported to occur at high 
frequency (66%) in melanoma with lower frequencies in colon and other tumours (Davies et 
al. 2002); BRAF is thus considered to be an important therapeutic target in melanoma 
(Bollag et al. 2010; Flaherty et al. 2010; Paraiso et al. 2011). Although over 30 single site 
missense mutations have been identified, 90% occur at nucleotide 1799 resulting in a T-A 
transition and an amino acid substitution at residue 600 (V600E) in the activation segment 
(Wan et al. 2004).  
In colorectal cancer (CRC) mutations in BRAF have been found in about 9-12% of tumours 
overall (Di Nicolantonio et al. 2008); (Deng et al. 2004; Jensen et al. 2008). However there is a 
distinct difference in frequency of BRAF mutations between mismatch repair (MMR) 
deficient (the microsatellite unstable (MSI-H) tumours) and the mismatch repair intact, 
microsatellite stable (MSS) tumours (Jensen et al. 2008). This is important clinically as 
tumours that are MSI-H have a better prognosis (Popat, Hubner, and Houlston 2005). BRAF 
is mutated in almost all sporadic CRCs with MSI-H (Jensen et al. 2008) but not in tumours 
arising in patients with an inherited form of MMR deficiency, hereditary nonpolyposis 
colon cancer (HNPCC), known as Lynch syndrome. Thus a major indication for BRAF 
mutation testing is for a differential diagnosis of Lynch Syndrome in a CRC that is MSI-H. If 
BRAF is mutated, the tumour is more likely to be sporadic, rather than the heritable type 
(Sharma and Gulley 2010).  
www.intechopen.com
 
Polymerase Chain Reaction 
 
144 
Mutated BRAF has also been associated with non response to anti-EGFR monoclonal 
antibody therapy (cetuximab or panitumamab) in metastatic CRC (mCRC) patients 
(Cappuzzo et al. 2008). In a larger study it was reported that 0/11 patients with a BRAF 
mutation responded to cetuximab or panitumumab, conversely none of the responders 
carried BRAF mutations (Di Nicolantonio et al. 2008). BRAF mutation has also been found to 
be a prognostic factor for poorer outcome in mCRC (Di Nicolantonio et al. 2008); (Price et al. 
2011); (Samowitz et al. 2005); (Saridaki et al. 2010); (Souglakos et al. 2009; Tol, Nagtegaal, 
and Punt 2009); (Van Cutsem et al. 2011). 
Although PCR-sequencing to detect BRAF mutations has been the gold standard technique, 
the improvement in instrumentation for high resolution analysis of PCR amplicon melt 
curves has opened up the way for the detection of single-base changes in short 
(approximately 100-200 bp) amplicons (Wittwer et al. 2003). Subsequently an improved 
method was developed, using melt curve analysis of an oligo-probe, annealing across the 
region of the mutation (Zhou et al. 2004). As the BRAF mutation is a class IV (T-A) change, 
we opted for this improved method using commercially available primer and probe 
sequences. Here we describe the optimisation and validation of this technique for the 
detection of the BRAF V600E mutation in formalin-fixed paraffin-embedded (FFPE) 
colorectal tumour tissue and, using the Kaplan-Meier method, the impact of this mutation 
on survival in the study cohort.  
2. Materials and methods  
2.1 Tumour collection and processing 
Patient samples were obtained from the MAX phase III clinical trial colorectal tumour 
cohort, described in Price et al. (Price et al. 2011). The MAX study design and eligibility 
criteria have been reported previously (Tebbutt et al. 2010). Eligible patients were enrolled 
in this trial between July 2005 and June 2007. After enrollment, patients were randomly 
assigned to receive capecitabine (C), capecitabine and bevacizumab (CB), and capecitabine, 
bevacizumab and mitomycin C (CBM). Patient demographic and clinical characteristics are 
shown in Table 1. Patients in these three groups were evaluated for tumour response or 
progression every 6 weeks by means of radiologic imaging. Treatment was continued until 
the disease progressed or until the patient could not tolerate the toxic effects. Samples of 
tumour tissue from archived FFPE specimens collected at the time of diagnosis were 
retrieved from storage at participating hospital pathology departments.  All patients 
participating in biomarker studies provided written informed consent at the time of study 
enrolment. Ethics approval was obtained centrally (Ethics Committee, Cancer Institute of 
NSW, Australia).  
2.2 DNA extraction 
DNA was extracted from 1-2 FFPE tissue sections (10 μm) mounted on plain glass slides, 
with an adjacent section stained with haematoxylin and eosin for reference. In cases that 
were deemed to have <50% presence of malignant crypts in the section (reviewed by a 
histopathologist), the tissue was manually dissected to ensure a high proportion of tumour 
cells. We used a single 10 μm section unless the size of the tissue section was <1 cm, in 
which case 2 10 μm sections were used. Paraffin was removed by xylene and DNA extracted 
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using the QIAamp DNA FFPE tissue kit (Qiagen, Valencia, CA, USA), according to the 
manufacturer's protocol. DNA was quantified using the Nanodrop (Thermo Scientific, 
Wilmington, DE, USA), ensuring the ratio 260/280 was >1.7.  
 
Baseline characteristic 
All patients (%) 
(n=471) 
BRAF MUT 
(%) (n=33) 
BRAF WT (%) 
(n=280) P 
Age (years)      
Median 67 71 68 0.27 
Range 32-86 36-85 32-86  
Sex Male 63 58 64 0.47 
ECOG performance status     
0-1 94 88 94 0.11 
2 6 12 6  
Capecitabine dosage     
2000mg/m2/day 67 60 68 0.38 
Disease-free interval > 12 
months 27 18 30 0.17 
Prior adjuvant 
chemotherapy 22 9 23 0.06 
Prior Radiotherapy 13 6 10 0.47 
Primary site of cancer     
Caecum 10 21 9 0.02 
Ascending colon 10 24 11 0.04 
Transverse colon 6 15 5 0.02 
Descending colon 3 6 4 0.48 
Sigmoid colon 30 18 32 0.11 
Recto-sigmoid colon 11 3 13 0.1 
Rectum 23 6 22 0.03 
Primary tumour resected 79 91 86 0.47 
Any metastases resected 10 3 9 0.23 
Extent of disease at 
baseline     
Local disease (colon or 
rectum) 36 15 33 0.03 
Liver metastases 75 62 75 0.19 
Lymph node metastases 47 59 45 0.09 
Lung metastases 39 21 41 0.03 
Bone metastases 4 0 4 0.23 
Peritoneal metastases 18 21 16 0.49 
Other metastases 10 24 10 0.01 
Table 1. Patient demographic and clinical characteristics  
(Reproduced with permission from the Journal of Clinical Oncology). 
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2.3 Mutation analyses 
Mutation status of BRAF was determined using high resolution melting analysis (HRM) 
PCR on the Rotorgene 6000 real-time instrument (Qiagen). BRAF HRM PCR (119 bp 
amplicon) was performed on 10 ng DNA in triplicate reactions using SsoFast™  EvaGreen® 
Supermix (Bio-Rad Laboratories Inc., Hercules, USA) and a primer/probe combination 
(RaZor® probe HRM assay, PrimerDesign, Southampton, UK). The sequences were 
5'ATGAAGACCTCACAGTAAAAATAGG (sense), CTCAATTCTTACCATCCACAAAATG 
(antisense) and 5'GTGAAATCTGGATGGAGTGGGTCCCATCA (probe). Appropriate 
mutant and wild type (WT) controls were included. A 'touch-down' PCR cycling protocol 
was used for the first 9 cycles to avoid primer mis-priming events and, due to the 
asymmetric design, 50 cycles were performed according to the manufacturer's protocol. The 
sensitivity of detection of mutant sequences was determined by assaying dilutions (100%, 
50%, 25%, 12.5%, 6.25%) of a tumour DNA sample, with known homozygous BRAF 
mutation status, in BRAF WT cell line DNA. Using the Rotor Gene 6000 (Qiagen) software 
analysis features for HRM, patient samples (n=315) were classified as having mutated 
(MUT) or WT BRAF respectively. Direct PCR sequencing was used to validate all mutant 
BRAF results and an additional 106 randomly chosen samples (45% of samples in total). The 
primers for BRAF sequencing reactions were designed in-house and obtained commercially 
(Geneworks, Thebarton, SA, Australia): 5'AATGCTTGCTCTGATAGGAAAA (sense) and 
5'AGTAACTCAGCAGCATCTCAGG (antisense). PCR products were purified using 
ExoSAP-IT (GE Healthcare, Buckinghamshire, UK) to remove unwanted deoxynucleotides 
and primers according to the manufacturer's protocol. Sequencing was performed by 
Flinders Sequencing Facility (Flinders Medical Centre, Bedford Park, SA, Australia) using 
BigDye Terminator v3.1 chemistry and the Applied Biosystems 3130xl Genetic Analyser 
(Life Technologies, Carlsbad, CA, USA).  
2.4 Statistical analyses 
All randomly assigned patients for whom data on BRAF mutation status were available 
were included in the analysis (n=313). PFS, the primary endpoint, was defined as the time 
from randomisation until documented evidence of disease progression, the occurrence of 
new disease or death from any cause. The secondary endpoint was overall survival (OS), 
defined as the time from randomisation until death from any cause. The PFS and OS of 
patients according to BRAF status were summarised with the use of Kaplan–Meier curves, 
and the difference between these groups was compared with the use of the log-rank test. All 
reported P values were two-sided. 
3. Results and discussion 
Although significantly less DNA was isolated from the microdissected sections (P=0.0001), 
the range of values obtained overall, 60 ng -31.3 µg, meant that all samples were well within 
the amount required for the PCR (30 ng) (Figure 1). 
In interpreting the HRM results, the first criterion of robust PCR amplification must be met 
(Figure 2A), so that the duplicates must show close Ct values (standard deviation <0.5) 
otherwise samples must be excluded from the HRM analysis and the PCR repeated. 
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Samples that show poor amplification with late Ct values may give erroneous results on 
HRM as shown in Figure 2B. The samples in the boxed area need to be excluded from the 
analysis to avoid misinterpretation of the difference plot as mutant calls. The poor 
amplification of a DNA sample may be due to the presence of inhibitors, and we have found 
that subsequent isolation of DNA from microdissected sections gave much better, more 
reproducible amplification results. This also suggests that minimising the amount of 
paraffin in the DNA preparation may be contributing to the improvement in PCR 
performance.  
whole sections microdissected
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Fig. 1. Dot plot of DNA yields. The average amount of DNA obtained from whole sections 
was 6.5±0.25 μg and from manually microdissected sections 4.2±0.48 μg.  
The positioning of the normalisation regions 1 and 2 in the first HRM analysis window is 
also a very important parameter in the correct calling of genotypes. This is user-defined and 
performed separately for HRM analysis of the probe region or the amplicon region. The 
correct positioning may be determined by monitoring the normalised graph to show the 
best separation of mutant versus WT curves. 
To determine the level of sensitivity of detection, serial doubling dilutions of a tumour 
sample carrying a homozygous BRAF V600E mutation were tested. The difference graph, 
normalised to the WT control, shows that the mutation could be detected down to a dilution 
of 6.25% mutant DNA in WT DNA (Figure 3A). Although there is a distinct difference 
between the WT control used for normalisation and the 6.25% and 12.5% dilutions, in 
practice the software cannot call these with any confidence. From the normalised graph and 
the melt curves graph (Figure 3B and 3C), 25% mutant DNA appears to be the lower limit of 
detection. However to increase the probability of correctly assigning a genotype we aimed 
for at least 50% epithelial tumour cells, hence all of the tumour tissue in the cohort was 
reviewed to ensure at least 50% epithelial tumour cells were present. Manual 
microdissection was performed in 1/5 of the cohort to ensure >50% enrichment of tumour 
cells, relative to muscularis mucosa and other cell types such as lymphoid aggregates, in the 
sample.  
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Fig. 2. A: amplification curves; B: difference plot normalised to WT. The boxed curves in A 
show samples with aberrant late amplification. The same samples boxed in B show the 
abnormal difference plots that could be incorrectly interpreted as mutant. Black arrow in B 
points to the heterozygous mutant control, red arrow shows the homozygous mutant 
control. 
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Fig. 3. A: Difference plot normalised to WT, with dilutions of homozygous MUT control 
DNA in WT DNA shown in replicate view (average of 3 for each dilution). Arrows indicate 
the plots for the dilutions of MUT control DNA in WT DNA from 100% MUT to 6.25%MUT; 
B: Normalised melting curves of the probe region. From this view it was not possible to 
distinguish the 12.5% or 6.25% dilutions of mutant sequence from WT; C: Melt curve 
showing Tm's for both the probe region and amplicon. The probe region HRM analysis was 
much easier to interpret than the amplicon HRM, however the 12.5% and 6.25%dilutions 
were indistinguishable from WT pattern.  
We have found that it was of critical importance to select the control genotypes (WT or 
mutant) for the normalisation carefully. The DNA of these controls needed to be extracted 
from a similar tissue (i.e. colonic tissue FFPE), and be processed in exactly the same way as 
the test samples. Using cell line derived DNA as the controls resulted in too many mutation 
calls with low confidence (false positives), however when we used tumour samples of 
known BRAF status as the controls, the confidence of the software calls of the test samples 
reached >99%. Often we found it was more informative to look at the shape of the curves in 
the difference plot, even if a curve deflected away from the horizontal normalised line, the 
angle of deflection was much greater for mutant genotypes and shallower for WT (Figure 4). 
This visual interpretation usually correlated with the software calls and was a useful adjunct 
in interpretation where the confidence of the software calls was low. 
Sequencing was used to validate the results and correlated with the HRM results. In some 
cases though sequencing showed a very small A peak which could be overlooked whereas 
HRM showed a very convincing shift and was called as a mutation with 99% confidence. An 
example is shown in Figure 5. 
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Fig. 4. Sequencing result and corresponding HRM analysis. A: Difference graph normalized 
to WT control (duplicates), blue arrow shows heterozygous control, green arrow pt 109, red 
arrow homozygous MUT control. Boxed area shows WT samples. Inset is the sequencing 
trace (Chromas Lite software) of patient (pt) 109, red arrow showing mutant (A) amongst 
WT (T) sequence. B: Normalised melt curve of probe region; black boxed area shows 
homozygous mutant control and 2 samples including pt 109, arrow points to the 
heterozygote mutant control,  blue box shows WT control and WT samples. C: Melt curve 
analysis, red trace WT, black trace homozygous MUT control, purple trace pt 109.  
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Fig. 5. An example of a sequencing result (pt 269) called WT (T) by the sequencing software 
that did in fact show a small A peak. The difference plot of the HRM analysis (normalized to 
WT control) showed a definite downward shifted curve (green arrow) between the 
homozygous BRAF MUT control (red arrow) and the heterozygous control (blue arrow). 
The boxed curves show the WT samples.  
Of 471 patients who underwent random assignment, a total of 315 tumour specimens (n=103 
from the capecitabine group, n=111 from the CB group, and n=101 from the CBM group, 
accounting for 66.9% of the total study population) were examined for BRAF mutation 
status by HRM. BRAF V600E mutations were detected in 10.5% of 313 tumours (2 samples 
were not evaluable). A proportion of samples were also genotyped using sequencing and 
showed 100% correlation with the HRM result.  
A total of 313 patients were included in the survival analysis with a median follow-up time 
of 26.5 months (range, 0.4 to 37.6 months). There was no significant difference in PFS 
between patients with WT tumours and those with mutated tumours. The median PFS was 
4.5 months among the patients with V600E tumours as compared with 8.2 months among 
those with WT tumours (HR: BRAF WT vs MUT, 0.80; 95% CI, 0.54 to 1.18; P=0.26). In 
contrast, there was a significant difference in OS between patients with WT tumours and 
those with V600E tumours. The median OS was 8.6 months among the patients with 
mutated BRAF tumours as compared with 20.8 months among those with WT tumours (HR: 
BRAF WT vs MUT, 0.49; 95% CI, 0.33 to 0.73; P=0.001) (Figure 6). BRAF status remained 
prognostically significant after adjustment of pre-defined baseline prognostic factors 
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including age, sex, ECOG performance status, inoperable local disease, and prior 
chemotherapy (HR: BRAF WT vs MUT, 0.45; 95% CI, 0.30 to 0.68; P<0.0001).  
 
Fig. 6. Kaplan-Meier analysis for overall survival comparing patients WT or MUT for BRAF . 
The curves are significantly different (P=0.001, log-rank test). Reproduced with permission 
from the Journal of Clinical Oncology. 
4. Conclusion 
HRM analysis is a useful fast technique to determine BRAF mutations using the platform of 
real-time PCR. It is both reproducible and reliable provided the preceding guidelines are 
followed and rigorous attention is given to the PCR performance as well as to the use of the 
software analysis package. Here we have described how the technique can be applied to the 
analysis of DNA extracted from archived FFPE tissue sections, which in many cases is the 
only source of tumour tissue available for retrospective analyses. The survival analysis 
showed that metastatic CRC patients with tumours carrying the V600E mutation had 
significantly poorer overall survival outcomes compared to those without the mutation. This 
HRM analysis could equally be applied to the assessment of tumours from patients 
diagnosed with other diseases known to have a significant BRAF mutation rate. 
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